情报报告

Hims & Hers and Noom add peptide prescriptions to their telehealth offerings

Two of the largest US telehealth players moved into compounded peptides after HHS eased the way for compounding pharmacies to supply them.

INSIGHTEX Editorial Desk

阅读约 2 分钟

Hims & Hers and Noom add peptide prescriptions to their telehealth offerings情报报告

What happened

Telehealth providers Hims & Hers and Noom each launched peptide programs this week, saying they will write prescriptions for patients who qualify, STAT reported. The rollouts follow a move by the Department of Health and Human Services that lowered barriers for compounding pharmacies to supply peptide drugs, with BPC-157 cited as one example.

Synthetic peptides are short chains of amino acids. Once favored mainly by bodybuilders, some have drawn wider interest from consumers seeking more muscle, energy, libido or faster injury recovery. Many compounded versions sold to the public remain experimental. They lack Food and Drug Administration approval, and no randomized controlled trials have established their safety or effectiveness in people.

Smaller telehealth firms were already prescribing peptides. The entry of Hims, whose market capitalization exceeds $3.5 billion, and Noom, a privately held company valued at $3.7 billion, marks a notable step for the category in the US, according to the report.

Context

Interest in peptides has spread beyond bodybuilding circles into the broader wellness market. HHS has given the drugs prominence under Health Secretary Robert F. Kennedy Jr., who has openly championed peptides. Before this week, prescriptions for these compounds came mainly through smaller telehealth companies rather than the sector's biggest names.

来源STAT

简报

一封邮件,尽览一周科技要闻。

每周精选值得一读的报道。可随时退订。